Table 1.
Baseline Characteristics of the On-Treatment and Pretreatment Groups Used for Microarrays and Quantitative Real-Time PCR
| Microarray Only |
Microarray and Real-Time PCR |
|||
|---|---|---|---|---|
| On-Treatment Group (n = 11) | Pretreatment Group (n = 19) | On-Treatment Group (n = 21) | Pretreatment Group (n = 31) | |
| Gender (male/female) | 5/6 | 10/9 | 13/8 | 19/12 |
| Age | 45.7 ± 6.9 | 51.7 ± 4.5 | 44.9 ± 5.3 | 51.6 ± 6.0 |
| Ethnicity | ||||
| African American | 6 | 8 | 9 | 14 |
| Caucasian | 5 | 11 | 12 | 17 |
| Treatment response | ||||
| RR | 6 | 5 | 10 | 10 |
| SR | 5 | 10 | 11 | 14 |
| Naive | NA | 4 | NA | 7 |
| Baseline HCV RNA | ||||
| >6 log copies/mL | 6 | 6 | 13 | 16 |
| <6 log copies/mL | 5 | 13 | 8 | 15 |
| Biopsy stage* | ||||
| 0 | 3 | 3 | 7 | 4 |
| 1 | 5 | 10 | 10 | 18 |
| 2 | 3 | 1 | 3 | 4 |
| 3 | 0 | 5 | 1 | 5 |
| 4 | 0 | 0 | 0 | 0 |
| Biopsy grade* | ||||
| 0 | 0 | 0 | 0 | 0 |
| 1 | 3 | 5 | 9 | 10 |
| 2 | 8 | 9 | 12 | 15 |
| 3 | 0 | 5 | 0 | 6 |
| 4 | 0 | 0 | 0 | 0 |
*
The biopsy stages and grades follow the Batts and Ludwig scoring system. For RRs, there was a ≥2 log copies/mL decline in HCV RNA by 4 weeks of treatment. For SRs, there was a <2 log copies/mL decline in HCV RNA by 4 weeks of treatment. Abbreviations: HCV, hepatitis C virus; NA, not applicable; PCR, polymerase chain reaction; RR, rapid responder; SR, slow responder.